Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;105(3):256-64.
doi: 10.5935/abc.20150078. Epub 2015 Jul 21.

Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure

[Article in English, Portuguese]
Affiliations

Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure

[Article in English, Portuguese]
Marcelo Rodrigues dos Santos et al. Arq Bras Cardiol. 2015 Sep.

Abstract

Background: Testosterone deficiency in patients with heart failure (HF) is associated with decreased exercise capacity and mortality; however, its impact on hospital readmission rate is uncertain. Furthermore, the relationship between testosterone deficiency and sympathetic activation is unknown.

Objective: We investigated the role of testosterone level on hospital readmission and mortality rates as well as sympathetic nerve activity in patients with HF.

Methods: Total testosterone (TT) and free testosterone (FT) were measured in 110 hospitalized male patients with a left ventricular ejection fraction < 45% and New York Heart Association classification IV. The patients were placed into low testosterone (LT; n = 66) and normal testosterone (NT; n = 44) groups. Hypogonadism was defined as TT < 300 ng/dL and FT < 131 pmol/L. Muscle sympathetic nerve activity (MSNA) was recorded by microneurography in a subpopulation of 27 patients.

Results: Length of hospital stay was longer in the LT group compared to in the NT group (37 ± 4 vs. 25 ± 4 days; p = 0.008). Similarly, the cumulative hazard of readmission within 1 year was greater in the LT group compared to in the NT group (44% vs. 22%, p = 0.001). In the single-predictor analysis, TT (hazard ratio [HR], 2.77; 95% confidence interval [CI], 1.58-4.85; p = 0.02) predicted hospital readmission within 90 days. In addition, TT (HR, 4.65; 95% CI, 2.67-8.10; p = 0.009) and readmission within 90 days (HR, 3.27; 95% CI, 1.23-8.69; p = 0.02) predicted increased mortality. Neurohumoral activation, as estimated by MSNA, was significantly higher in the LT group compared to in the NT group (65 ± 3 vs. 51 ± 4 bursts/100 heart beats; p < 0.001).

Conclusion: These results support the concept that LT is an independent risk factor for hospital readmission within 90 days and increased mortality in patients with HF. Furthermore, increased MSNA was observed in patients with LT.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Length of hospital stay in patients with heart failure and low testosterone (LT; n = 66) and normal testosterone (NT; n = 44). The LT group had a longer hospitalization stay than the NT group at the first admission. *Between group difference, p = 0.008.
Figure 2
Figure 2
Kaplan–Meier readmission curves within the 1-year follow-up in patients with heart failure. The low testosterone group showed more cumulative readmissions than the normal testosterone group within the year (p = 0.001). The 1-year follow-up started at hospital discharge (time zero).
Figure 3
Figure 3
Kaplan–Meier survival curves within the 1-year follow-up in patients with heart failure. The low testosterone group had a higher mortality rate than the normal testosterone group within the year (p = 0.001). The 1-year follow-up started at hospital discharge (time zero).

Similar articles

Cited by

References

    1. Rohde LE, Clausell N, Ribeiro JP, Goldraich L, Netto R, William Dec G, et al. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. Int J Cardiol. 2005;102(1):71–77. - PubMed
    1. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA. 2013;309(15):1593–1594. - PubMed
    1. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61(4):391–403. - PubMed
    1. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, et al. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol. 2008;52(21):1702–1708. - PMC - PubMed
    1. Dracup K, Walden JA, Stevenson LW, Brecht ML. Quality of life in patients with advanced heart failure. Pt 1J Heart Lung Transplant. 1992;11(2):273–279. - PubMed

Publication types